Skip to content
OpenCapital
Get started

Cumberland Pharmaceuticals CPIX G&A

G&A at other companies

RFL
Rafael Holdings, Inc.RFL
$2.14M-32.5%

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+138%
Enterprise value$90.91M+207%
P/S2.3×+1.3×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%—

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio1×-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's G&A?
Cumberland Pharmaceuticals (CPIX) reported G&A of $2.55M in Q1 2026.
How has Cumberland Pharmaceuticals's G&A changed year-over-year?
Cumberland Pharmaceuticals's G&A increased by 3.7% year-over-year, from $2.46M to $2.55M.
What is the long-term trend for Cumberland Pharmaceuticals's G&A?
Over 4 years (2021 to 2025), Cumberland Pharmaceuticals's G&A has grown at a 5.1% compound annual growth rate (CAGR), from $9.78M to $11.95M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.